Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Patient controlled analgesia for adults with sickle cell disease awaiting admission from the emergency department
source: Pain Research and Management
year: 2016
authors: Santos J, Jones S, Wakefield D, Grady J, Andemariam B
summary/abstract:Background:
A treatment algorithm for sickle cell disease (scd) pain in adults presenting to a single emergency department (ed) was developed prioritizing initiation of patient controlled analgesia (pca) for patients awaiting hospitalization.
Objectives:
Evaluate the proportion of ed visits in which pca was started in the ed.
Methods:
A two-year retrospective chart review of consecutive scd pain ed visits was undertaken. Data abstracted included pca initiation, low versus high utilizer status, pain scores, bolus opioid number, treatment times, and length of hospitalization.
Results:
258 visits resulted in hospitalization. Pca was initiated in 230 (89%) visits of which 157 (68%) were initiated in the ed. Time to pca initiation was longer when pca was begun after hospitalization versus in the ed (8.6 versus 4.5 hours, p < 0.001). Ed pca initiation was associated with fewer opioid boluses following decision to admit and less time without analgesic treatment (all p < 0.05). Mean pain intensity (mpi) reduction did not differ between groups. Among visits where pca was begun in the ed, low utilizers demonstrated greater mpi reduction than high utilizers (2.8 versus 2.0, p = 0.04).
Conclusions:
Ed pca initiation for scd-related pain is possible and associated with more timely analgesic delivery.
DOI: 10.1155/2016/3218186
read more full text
+myBinderRelated Content
-
Paula Tanabe, RN, PhDPaula Tanabe, PhD, RN, MPH, FAEN, FAAN, ...
-
Blood Transfusions for Sickle Cell DiseaseDuring a blood transfusion, a person (th...
-
Amber Yates, MDDr. Amber Yates is an Associate Director...
-
UH BEATS programhttps://www.youtube.com/watch?v=lzvl_tyv...
-
Early clinical trial data show gene therapy reversing sickle cell anemiaAfter over a decade of preclin...
-
Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell diseaseEffective medical management for sickle ...
-
FDA Approves First Targeted Therapy to Treat Patients with Painful Complication of Sickle Cell DiseaseToday, the U.S. Food and Drug Administra...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.